Browse studies

Find your next paid study

1 recruiting study matching your filters

An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subj…

Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more

Estimated

~$10 – $8,750

Neomorph, IncNCT07300241